<DOC>
	<DOCNO>NCT01051414</DOCNO>
	<brief_summary>To assess efficacy safety profile co-administration BMS-790052 BMS-650032 24 week treatment .</brief_summary>
	<brief_title>An Anti-viral Combination Study With Japanese Hepatitis C Infection ( HCV ) Subject</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Subjects chronically infect HCV Genotype 1 HCV RNA viral load â‰¥ 10*5* IU/mL ( 100,000 IU/mL ) screen Subjects evidence liver cirrhosis Evidence HCC Coinfection hepatitis B virus , HIV</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>